Trial · NCT07569887
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Standardized Uptake Value (SUV) | Before and at 6 months after surgical treatment of unruptured arteriovenous malformation | Changes in Standardized Uptake Value (SUV) measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere) |
| Primary | Change in K1 Transfer Constant | Before and at 6 months after surgical treatment of unruptured arteriovenous malformation | Change in the K1 transfer constant, representing the transfer of the tracer from the plasma compartment to the tissue compartment, measured by 18F-FDG positron emission tomography (PET) measured in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : mL.g-1.min-1 |
| Primary | Change in Ki Net Influx Rate Constant | Before and at 6 months after surgical treatment of unruptured arteriovenous malformation | Change in Ki net influx rate constant measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : mL.g-1.min-1 |
| Primary | Change in Cerebral Metabolic Rate of glucose (CMRglu) | Before and at 6 months after surgical treatment of unruptured arteriovenous malformation | Change in cerebral metabolic rate of glucose (CMRglu) measured by 18F-FDG positron emission tomography (PET) in different brain regions (arteriovenous malformation region, arteriovenous malformation hemisphere including the arteriovenous malformation region, arteriovenous malformation hemisphere excluding the arteriovenous malformation region, contralateral hemisphere). Unit : µmol.100g-¹.min-¹ |
| Secondary | Headache impact | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Headache impact assessed by the total score on the Headache Impact Test - 6 items (HIT-6) Total score between 36 and 78. A higher score indicates a greater functional impact. |
| Secondary | Visual attention and processing speed | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Visual attention and processing speed assessed by completion time on the Trail Making Test - Part A (TMT-A) |
| Secondary | Cognitive flexibility and executive control | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Cognitive flexibility and executive control assessed by completion time on the Trail Making Test - Part B (TMT-B) |
| Secondary | Inhibition and selective attention | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Inhibition and selective attention assessed by completion times and number of errors on the Stroop Test |
| Secondary | Working memory | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Working memory assessed by scores on the Digit Span subtest of the Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) |
| Secondary | Global verbal episodic memory | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Global verbal episodic memory assessed by scores on the 16-item Free Recall / Cued Recall test (RL/RI-16) |
| Secondary | Phonemic and semantic verbal fluency | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Phonemic and semantic verbal fluency assessed by the number of words produced on verbal fluency tests |
| Secondary | Ecological executive functioning | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Ecological executive functioning assessed by raw scores and composite indices on the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) |
| Secondary | Visual constructive abilities and visual memory | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Visual constructive abilities and visual memory assessed by scores on the Rey-Osterrieth Complex Figure Test |
| Secondary | Visual attention and spatial exploration | Before, at 3 months and 6 months after surgical treatment of unruptured arteriovenous malformation | Visual attention and spatial exploration assessed by the number of crossed-out targets, omissions, and their spatial distribution in the Bell Test. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07569887/registered